Utilizing comprehensive bioinformatic analysis, we found FGFR3 as a target for TME remodeling status and possibly as a predictor of clinical outcomes, including survival of bladder cancer patients, distant tumor metastasis, and immunotherapy response. This evidence concerns the gene FGFR3 and neoplasm.